Dextroamphetamine

Selected References:

- Anderson KN, et al. 2020. ADHD medication use during pregnancy and risk for selected birth defects: national birth defects prevention study, 1998-2011. J Atten Disord, 24(3):479-489.
- Bang Madsen K., et al. 2025. In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders – a population-based cohort study and meta-analysis. Molecular psychiatry, 30(9), 3885–3894.
- Benassayag Kaduri N, et al. 2024. Amphetamine use for attention deficit hyperactive disorder during breastfeeding and children's neurodevelopmental outcomes: A pilot study. Psychiatry research, *339*, 116047.
- Cohen JM, et al. 2017. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol, 130(6):1192-1201.
- Golub M, et al. 2005. NTP CERHR expert panel report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Birth Defects Res B Dev Reprod Toxicol, 74(6):471-584.
- Hasan SA, et al., 2026. Prescription Stimulant Continuation in Pregnancy and Birth Outcomes. Journal of attention disorders, 30(3), 315–328.
- Huybrechts KF, et al. 2018. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry, 75(2):167-175.
- Ilett KF, et al. 2007. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J Clin Pharmacol, 63(3):371-375.
- Naeye RL, 1983. Maternal use of dextroamphetamine and growth of the fetus. Pharmacology, 26(2):117-120.
- Newport DJ, et al. 2016. Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. J Clin Psychiatry. 77(11):1538-45.
- Norby U et al. 2017. Perinatal outcomes after treatment with ADHD medication during pregnancy. Pediatrics 140(6).
- Ornoy A, 2018. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res, 35:46
- Öhman I, et al. 2015. Narcolepsy treated with racemic amphetamine during pregnancy and breastfeeding. J Hum Lact 31:374-6.
- Pham MN, et al. 2022. The adverse association between stimulant use for attention deficit hyperactivity disorder (ADHD) and semen parameters. Andrologia, *54*(2), e14315.
- Poulton AS et al. 2018. Perinatal outcomes of women diagnosed with attention-deficit/hyperactivity disorder: An Australian population-based cohort study. CNS Drugs 32(4):377-386.
- Rastegar-Pouyani N., et al. 2025. Prenatal Exposure to Methamphetamine and Its Association With Birth Outcomes: A Meta-Analysis. Birth defects research, *117*(7), e2488
- Rose SJ, et al., 2020. Amphetamine–dextroamphetamine and pregnancy: neonatal outcomes after prenatal prescription mixed amphetamine exposure. Journal of Attention Disorders, 25(9):1295-1301.
- Russell DJ, et al. 2024. Investigating maternal and neonatal health outcomes associated with continuing or ceasing dexamphetamine treatment for women with attention-deficit hyperactivity disorder during pregnancy: a retrospective cohort study. Arch Womens Ment Health; 27(5):785-794.
- Srinivas C, et al. 2025. Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage. The British journal of psychiatry: the journal of mental science, 1–7.
- Srinivas, C, et al. 2025. Attention-Deficit/Hyperactivity Disorder Medication Use in Pregnancy and Risk of Preterm Birth: A Population-Based Cohort Study. Paediatric and perinatal epidemiology, 10.1111/ppe.70031.
- Suarez EA, et al. 2024. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. JAMA psychiatry, *81*(5), 477–488.

- U.S. Food and Drug Administration. 2017. Vyvanse ® (lisdexamfetamine dimesylate). [Accessed 3/2026]. from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.

Dextroamphetamine

Selected References:

- Bakhireva LN, et al., 2007. Safety of leukotriene receptor antagonists in pregnancy. Journal of Allergy and Clinical Immunology, 119; 618-625.
- Cavero-Carbonell C, et al. 2017. Fetal exposure to montelukast and congenital anomalies: a population based study in Denmark. Birth Defects Res, 109(6):452-459.
- Datta P, et al. 2017. Transfer of montelukast into human milk during lactation. Breastfeed Med, 12:54-57. Hatakeyama S, et al., 2022. The safety of pranlukast and montelukast during the first trimester of pregnancy: a prospective, two-centered cohort study in Japan. Congenit Anom (Kyoto), 62(4):161-168.
- Fareed A et al. 2024. Montelukast use in pregnancy: A systematic review and meta-analysis of maternal and fetal outcomes in asthma treatment. Congenit Anom (Kyoto), 64(6):220-227. doi: 10.1111/cga.12581. Epub 2024 Aug 11. PMID: 39129058.
- Merck Sharp & Dohme Corp. 2022. Singulair product labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm
- Nelsen LM, et al., 2012. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. J Allergy Clin Immunol, 129(1):251-254.e1-6.
- Sarkar M, et al. 2009. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes Eur J Clin Pharmacol, 65(12):1259-1264.

- The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). 2000. The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol, 84:475-480.
- Tsai HJ et al. Use of Leukotriene-Receptor Antagonists During Pregnancy and Risk of Neuropsychiatric Events in Offspring. 2023. JAMA Netw Open, 6(3): e231934. doi: 10.1001/jamanetworkopen.2023.1934. PMID: 36881413; PMCID: PMC9993182.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.

Dextroamphetamine

Selected References:

- Centers for Disease Control and Prevention. 2025. About RSV. Available at https://www.cdc.gov/rsv/about/index.html. Accessed 4 March 2026.
- Centers for Disease Control and Prevention. 2024. RSV Vaccine Guidance for Pregnant Women. Available at https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html. Accessed 4 March 2026.
- DeSilva M. 2025. Prenatal RSVpreF Vaccine Safety 2023–2024 Respiratory Season: The Vaccine Safety Datalink (VSD). Centers for Disease Control and Prevention. Presented at: Meeting of the Advisory Committee on Immunization Practices (ACIP); June 25, 2025; Atlanta, Georgia. Available at: https://www.cdc.gov/acip/downloads/slides-2025-06-25-26/04a-DeSilva-Mat-Peds-RSV-508.pdf. Accessed 4 March 2026.
- Fleming-Dutra KE, et al. 2023. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR Morb Mortal Wkly Rep; 72(41):1115-1122.
- Kampmann B, et al. 2023. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med; 388:1451-146.

- Marchand GJ, et al. 2024. RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy. Obstet Gynecol Sci 67(6): 511-524.
- Michnick AI, et al. 2026. Interim safety of RSVpreF vaccination during pregnancy. *JAMA*. 335(5):456–459.
- U.S. Food and Drug Administration. 2023 (Revised 2025). AbrysvoTM Prescribing Information. Available at: https://www.fda.gov/media/168889/download. Accessed 4 March 2026.
- Son M, et al. 2024. Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes. JAMA Netw Open; 7(7):e2419268.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.

Dextroamphetamine

Selected References:

- Anderson PO. 2021. Monoclonal antibodies during breastfeeding. Breastfeed Med; 16(8):591-593.
- Jang W, et al. 2025. Use of biologics to treat asthma during pregnancy and adverse events in pregnant women and newborns: A global pharmacovigilance analysis. Int Arch Allergy Immunol; 186(9):875-888.
- Kasuya A, et al. 2019. Successful control of severe eosinophilic granulomatosis with polyangiitis in pregnancy and perinatal period: A use of mepolizumab. The Journal of Dermatology; 46(9):e309-e311.
- Marques Simões J, et al. 2026. Safety and Efficacy of Mepolizumab during Pregnancy and Postpartum. Acta Med Port; 39(3):239-240.
- Nucala® Prescribing Information. Revised 1/2022. Available online at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IF

U-COMBINED.PDF.

- Ramos CL, Namazy J. 2023. Monoclonal antibodies (biologics) for allergic rhinitis, asthma, and atopic dermatitis during pregnancy and lactation. Immunol Allergy Clin North Am; 43(1):187-197.
- Shakuntulla F, Chiarella SE. 2022. Safety of biologics for atopic diseases during pregnancy. J Allergy Clin Immunol Pract; 10(12):3149-3155.
- Sitek AN, et al. 2023. Risks and safety of biologics: A practical guide for allergists. World Allergy Organ J; 16(1):100737.
- Smith DA, et al. 2011. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet; 50(4):215-227.
- Vittorakis SK, et al. 2022. Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy. Respir Med Case Rep; 28;41:101785.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.

Dextroamphetamine

Selected References:

- DeSisto CL, et al. 2021. Risk of stillbirth among women with and without COVID-19 at delivery hospitalization – United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep. 70(47):1640-1645.
- Hashemian SMR, et al. 2022. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother. 146:112517.
- Li G. et al. 2023. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 22(6):449-475.
- Kasehagen L, et al. 2021. COVID-19 – associated deaths after SARS-CoV-2 infection during pregnancy – Mississippi, March 1, 2020 – October 6, 2021. MMWR Morb Mortal Wkly Rep. 70(47):1646-1648.
- Merck Sharp & Dohme LLC. 2024. Lagevrio product labeling. Available at:

https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1b0da643-ab23-4a0b-a9ec-a434522446d0&type=display. Accessed 10 August 2026.

- Pagliano P et al. 2022. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert Opin Drug Discov. 17(12):1299-1311.
- Regan AK, et al. 2022. SARS-CoV-2 infection during pregnancy and associated perinatal health outcomes: a national US cohort study. J Infect Dis. 225(5):759-767.
- U.S. Food & Drug Administration, Antimicrobial Drugs Advisory Committee. November 30, 2021. Molnupiravir. Available at: https://www.fda.gov/media/165856/download. Accessed 10 August 2026.
- U.S. Food & Drug Administration. 2021 (Revised October 2023). Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir. Available at https://www.fda.gov/media/155054/download. Accessed 10 August 2026.
- Wan EYF, et al. 2025. Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and molnupiravir versus monotherapy with molnupiravir or nirmatrelvir-ritonavir in hospitalized COVID-19 patients: A target trial emulation study. Int J Infect Dis161:108097.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.